Primary breast cancer in elderly women: Biological profile and relation with clinical outcome

Critical Reviews in Oncology/Hematology

Volumn 45, Issue 3, 2003, Pages 313-325

  Daidone, Maria Grazia ^a   Coradini, Danila ^a   Martelli, Gabriele ^a   Veneroni, Silvia ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Biomarkers; Breast cancer; Elderly patients; Predictive factors; Prognosis

Indexed keywords

BIOLOGICAL MARKER; DNA; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; TAMOXIFEN;

AGE; AGED; BIOACCUMULATION; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; COST BENEFIT ANALYSIS; FOLLOW UP; HUMAN; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

EID: 0037334579     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(02)00144-0     Document Type: Review

References (33)

1. Baranofsky A., Myers M.H. Cancer incidence and survival in patients 65 years of age and older. Cancer. 36:1986;26-41.
2. Surveillance, Epidemiology, and End Results (SEER) Program: Public use CD-ROM (1973-1995), Bethesda (MD): Cancer Statistics Branch, National Cancer Institute; 1998.
3. Franceschi S., La Vecchia C. Cancer epidemiology in the elderly. Crit. Rev. Oncol./Hematol. 39:2001;219-226.
4. Pike M.C., Krailo M.D., Herderson B.E., Casagrande J.T., Hoel D.G. Hormonal risk factors, 'breast tissue age' and the age-incidence of breast cancer. Nature. 303:1983;767-770.
5. Bast R.C., Ravdin P., Hayes D.F., et al. Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol. 19:2001;1865-1878.
6. National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000. J Natl Cancer Inst 2001;93:979-89.
7. Goldhirsch A., Glick J.H., Gelber R.D., Coates A.S., Senn H.-J. Meeting Highlights: International Consensus Panel on the treatment of primary breast cancer. J. Clin. Oncol. 19:2001;3817-3827.
8. 3H-Thymidine labelling index, hormone receptors, and ploidy in breast cancers in elderly patients. Breast Cancer Res. Treat. 20:1991;19-24.
9. Daidone M.G., Luisi A., Silvestrini R., Di Fronzo G. Biologic characteristics of primary breast cancer in the elderly. Balducci L., Lyman G.H., Ershler W.B. Comprehensive geriatric oncology. 1998;197-200 Harwood Academic Publishers, Amsterdam.
10. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 351:1998;1451-1467.
11. Diab S.G., Elledge R.M., Clark G.M. Tumor characteristics and clinical outcome of elderly women with breast cancer. J. Natl. Cancer Inst. 92:2000;550-556.
12. Anderson W.F., Chu K.C., Chatterjee N., Brawley O., Brinton L.A. Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database. J. Clin. Oncol. 19:2001;18-27.
13. Silvestrini R., Daidone M.G., Luisi A., et al. Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer. J. Clin. Oncol. 13:1995;697-704.
14. Silvestrini R., Benini E., Daidone M.G., et al. The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J. Natl. Cancer Inst. 86:1994;499-504.
15. Silvestrini R., Daidone M.G., Del Bino G., Mastore M., Di Fronzo G., Boracchi P. Prognostic significance of proliferative activity and ploidy in node-negative breast cancers. Ann. Oncol. 4:1993;213-219.
16. 3H-thymidine labelling index in breast cancer. The SICCAB Group for Quality Control of Cell Kinetic Determination. Cell. Prolif. 24:1991;437-445.
17. Piffanelli A., Giovannini G., Pelizzola S., De Bortoli M., Catozzi L., Giganti. Steroid receptor assays: an Italian quality assessment program. Ann. Ist. Super Sanità 27:1991;523-529.
18. Daidone M.G., Luisi A., Martelli G., et al. Biomarkers and outcome after tamoxifen treatment in node-positive breast cancers from elderly women. Br. J. Cancer. 82:2000;270-277.
19. Silvestrini R., Luisi A., Zambetti M., et al. Cell proliferation and outcome following Doxorubicin plus CMF regimens in node-positive breast cancer. Int. J. Cancer. 87:2000;405-411.
20. Daidone M.G., Silvestrini R. Prognostic and predictive role of proliferation indices. J. Natl. Cancer Inst. Monogr. 30:2001;27-35.
21. Daidone M.G., Luisi A., Veneroni S., Benini E., Silvestrini R. Clinical studies of bcl-2 and treatment benefit in breast cancer patients. Endocrine-related Cancer. 6:1999;61-68.
22. Pichon M.F., Milgrom E. Oestrogen receptor negative-progesterone receptor positive phenotype in 1,211 breast tumours. Br. J. Cancer. 65:1992;895-897.
23. Fuqua S.A.W., Fitzgerald S.D., Chamness S.C., et al. Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res. 51:1991;105-109.
24. Elston C.W., Ellis I.O. Pathological prognostic factor in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 19:1991;403-410.
25. Hutchins L.F., Unger J.M., Crowley J.J., Coltman C.A. Jr., Albin K.S. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N. Engl. J. Med. 30:1999;2061-2067.
26. Kemeny M., Muss H.B., Kornblith A.B., Peterson B., Wheeler J., Cohen H.J. Proc. ASCO. 19:2000;2371.
27. Balducci L., Extermann M., Fentiman I., Monfardini S., Perrone F. Should adjuvant chemotherapy be used to treat breast cancer patients (≥70 years of age)? Eur. J. Cancer. 33:1997;1720-1724.
28. Yancik R., Ries L.G., Yates J.W. Breast cancer in aging women. A population-based study of contrasts in stage, surgery and survival. Cancer. 63:1989;976-981.
29. Castiglione M., Gelber R.D., Goldhirsch A. Adjuvant systemic therapy for breast cancer in the elderly: completing causes of mortality. International Study Group. J. Clin. Oncol. 8:1990;519-526.
30. Silliman R.A., Balducci L., Goodwin J.S., Holmes F.F., Leventhal E.A. Breast cancer care in old age: what we know, don't know, and do. J. Natl. Cancer Inst. 85:1993;190-199.
31. Scarpi E., De Paola F., Sarti M., et al. Biomarker prediction of clinical outcome in operable breast cancer patients treated with tamoxifen. Breast Cancer Res. Treat. 68:2001;101-110.
32. Paradiso A., Mangia A., Barletta A., et al. Randomised clinical trial of adjuvant chemotherapy in patients with node-negative, fast-proliferating breast cancer. Drugs. 45:1993;68-74.
33. Hayes D.F., Trock B., Harris A.L. Assessing the clinical impact of prognostic factors: when is 'statistically significant' clinically useful? Breast Cancer Res. Treat. 52:1998;305-319.